World Pharma AIRegister

All insights

Pharma

AI framework AGENT yields mRNA vaccines stable at 37 °C for two months

Solid-state mRNA–lipid nanoparticle formulations gave immune responses non-inferior to fresh vaccines in rodents and nonhuman primates, Nature Biotechnology reports.

By World Pharma AI Editorial2 min read2 sources

Researchers led by J. Tian published a study in Nature Biotechnology on 28 September 2026 describing AGENT, an AI-driven framework that combines high-throughput experimentation with Bayesian optimisation to engineer thermostable, solid-state mRNA vaccines12.

What the study reports

The formulations produced by AGENT retained full bioactivity after storage at 37 °C for 2 months2. They elicited immune responses that were non-inferior to fresh vaccines, and they supported cold-chain-free delivery using microneedle patches in rodents and nonhuman primates2. The published summary describes the improvement as one of thermostability in RNA vaccines achieved with AI, and places the work across biomaterials, biomedical engineering, nanoparticles and SARS-CoV-2 vaccine safety and efficacy studies12.

The approach builds on earlier work in the same journal on a microneedle vaccine printer for thermostable COVID-19 mRNA vaccines, published in Nature Biotechnology in 2024, and on a 2026 report in Drug Delivery and Translational Research of an mRNA-loaded microneedle patch using a clinically relevant lipid nanoparticle composition2. The optimisation method itself is long established: the authors cite a 2015 review of Bayesian optimisation in Proceedings of the IEEE2.

Two things are being claimed at once. The first is a product property, a solid-state mRNA–lipid nanoparticle vaccine that survives two months at body temperature without loss of bioactivity2. The second is a process property, that a data-efficient AI loop paired with high-throughput screening can reach such a formulation rapidly12. The published summary characterises AGENT as enabling "rapid engineering" of these formulations, without quantifying how many experiments or how much calendar time the loop required2.

What it means for the market

For vaccine manufacturers and the teams that plan their distribution, the relevant variable is storage at 37 °C rather than refrigeration or ultra-cold handling, combined with microneedle patch administration2. The study cites a 2025 review in Outbreak Management and Response on strategies for efficient storage and distribution of vaccines in resource-constrained environments, which is the setting the thermostability claim speaks to2. The sources do not quantify any cost, logistics or coverage benefit, so the commercial value of removing the cold chain is not established by this work.

For formulation and CMC groups, the interest is in the method. AGENT is presented as data-efficient, which matters where each experimental cycle is expensive and screening budgets are fixed12. The sources give no comparison against conventional formulation development in time, cost or number of candidates tested, so buyers of AI platforms have no benchmark here to hold a vendor to.

Nothing in the sources addresses regulation, reimbursement or procurement. No regulatory engagement, clinical trial, licensing arrangement or manufacturing partner is named12. Whether solid-state mRNA formulations and patch delivery can meet comparability expectations for an already approved product class remains unaddressed by this publication.

Caveats

The evidence is preclinical. Immunogenicity was assessed in rodents and nonhuman primates, with no human data reported, and the sources give no animal numbers, no study design details and no immunological endpoints or effect sizes2. Non-inferiority is asserted against fresh vaccine without a stated margin2. Stability is reported at a single temperature for a single duration, 37 °C for 2 months2.

The detail available publicly is also limited: the Nature Biotechnology research briefing is a summary of the full paper, and both the briefing and the primary article sit behind subscription access, with individual article purchase listed at USD 39.952.

Sources

  1. Accelerated discovery of thermostable mRNA–lipid nanoparticle vaccines using data-efficient AI (opens in a new tab)Nature Biotechnology · nature.com
  2. AI-guided optimization for thermostable mRNA vaccines (opens in a new tab)Nature Biotechnology · nature.com

This briefing summarises publicly available research and reporting for information only. It is not medical, investment or legal advice. Follow the sources listed for the primary research and reporting.